Initiate Phase 2 clinical trial of RP2 in HCC
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 May 2024
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Phase 2 clinical trial with RP2 in anti-PD1/PD-L1 progressed HCC of RP2 combined with atezolizumab and bevacizumab is expected to initiate in 2H 2024.”
What we found
Evidence strength A What the grades mean
The company confirmed in a February 2025 filing that it had enrolled the first patient in the Phase 2 clinical trial of RP2 in HCC, indicating the trial was initiated within the 2024 timeframe.
-
A Replimune Group, Inc. 8-K filed 2025-02-12
“Enrolled the first patient in a Phase 2 clinical trial with RP2 combined with atezolizumab and bevacizumab in anti-PD1/PD-L1 progressed HCC.” ✓ confirmed on the page
Market reaction: the shares moved +9.0% against the S&P 500 over the three sessions around the disclosure (11 Feb 2025 to 14 Feb 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 16 May 2024
Deadline 31 Dec 2024 (“2H 2024”) · wording expected
-
Version 2 · stated 8 Aug 2024
Deadline 31 Dec 2024 (“2H 2024”) · target 1 patient · wording expected
“A Phase 2 clinical trial with RP2 combined with atezolizumab and bevacizumab in anti-PD1/PD-L1 progressed HCC is expected to dose its first patient in 2H 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 clinical trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-REPL-002733 · Corrections policy